Abstract
For more than 20 years, the World Health Organization Western Pacific Region (WPR) has been polio-free. However, two current challenges are still polio-related. First, around half of poliomyelitis elderly survivors suffer late poliomyelitis sequelae with a substantial impact on daily activities and quality of life, experiencing varying degrees of residual weakness as they age. The post-polio syndrome as well as accelerated aging may be involved. Second, after the worldwide Sabin oral poliovirus (OPV) vaccination, the recent reappearance of strains of vaccine-derived poliovirus (VDPV) circulating in the environment is worrisome and able to persistent person-to-person transmission. Such VDPV strains exhibit atypical genetic characteristics and reversed neurovirulence that can cause paralysis similarly to wild poliovirus, posing a significant obstacle to the elimination of polio. Immunization is essential for preventing paralysis in those who are exposed to the poliovirus. Stress the necessity of maintaining high vaccination rates because declining immunity increases the likelihood of reemergence. If mankind wants to eradicate polio in the near future, measures to raise immunization rates and living conditions in poorer nations are needed, along with strict observation. New oral polio vaccine candidates offer a promissory tool for this goal.
Similar content being viewed by others
References
Racaniello VR, Baltimore D. Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc Natl Acad Sci U S A. 1981;78(8):4887–91.
Racaniello VR, Baltimore D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science. 1981;214(4523):916–9.
Agol VI. Molecular mechanisms of poliovirus variation and evolution. Curr Top Microbiol Immunol. 2006;299:211–59.
Ward CD, Stokes MA, Flanegan JB. Direct measurement of the poliovirus RNA polymerase error frequency in vitro. J Virol. 1988;62(2):558–62.
Arnold JJ, Cameron CE. Poliovirus RNA-dependent RNA polymerase (3Dpol): pre-steady-state kinetic analysis of ribonucleotide incorporation in the presence of Mg2+. Biochemistry. 2004;43(18):5126–37.
Wells VR, Plotch SJ, DeStefano JJ. Determination of the mutation rate of poliovirus RNA-dependent RNA polymerase. Virus Res. 2001;74(1–2):119–32.
Racaniello VR. Poliovirus neurovirulence. Adv Virus Res. 1988;34:217–46.
Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis. 1985;151(3):420–36.
Bigouette JP, et al. Progress toward polio eradication - worldwide, January 2019-June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1129–35.
Chard AN, et al. Progress toward polio eradication - worldwide, January 2018-March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(25):784–9.
Rachlin A, et al. Progress toward polio eradication - worldwide, January 2020-April 2022. MMWR Morb Mortal Wkly Rep. 2022;71(19):650–5.
Wilkinson AL, et al. Surveillance to track progress toward polio eradication - worldwide, 2020–2021. MMWR Morb Mortal Wkly Rep. 2022;71(15):538–44.
Malnou CE, et al. Effects of vaccine strain mutations in domain V of the internal ribosome entry segment compared in the wild type poliovirus type 1 context. J Biol Chem. 2004;279(11):10261–9.
Svitkin YV, Maslova SV, Agol VI. The genomes of attenuated and virulent poliovirus strains differ in their in vitro translation efficiencies. Virology. 1985;147(2):243–52.
Ochs K, et al. Impaired binding of standard initiation factors mediates poliovirus translation attenuation. J Virol. 2003;77(1):115–22.
Avanzino BC, et al. Molecular mechanism of poliovirus Sabin vaccine strain attenuation. J Biol Chem. 2018;293(40):15471–82.
de Breyne S, et al. Direct functional interaction of initiation factor eIF4G with type 1 internal ribosomal entry sites. Proc Natl Acad Sci U S A. 2009;106(23):9197–202.
Hellen CU, et al. A cytoplasmic 57-kDa protein that is required for translation of picornavirus RNA by internal ribosomal entry is identical to the nuclear pyrimidine tract-binding protein. Proc Natl Acad Sci U S A. 1993;90(16):7642–6.
Hunt SL, Jackson RJ. Polypyrimidine-tract binding protein (PTB) is necessary, but not sufficient, for efficient internal initiation of translation of human rhinovirus-2 RNA. RNA. 1999;5(3):344–59.
Meerovitch K, et al. La autoantigen enhances and corrects aberrant translation of poliovirus RNA in reticulocyte lysate. J Virol. 1993;67(7):3798–807.
Blyn LB, et al. Requirement of poly(rC) binding protein 2 for translation of poliovirus RNA. J Virol. 1997;71(8):6243–6.
Hellen CU, et al. The cellular polypeptide p57 (pyrimidine tract-binding protein) binds to multiple sites in the poliovirus 5’ nontranslated region. J Virol. 1994;68(2):941–50.
Kafasla P, et al. Polypyrimidine tract-binding protein stimulates the poliovirus IRES by modulating eIF4G binding. EMBO J. 2010;29(21):3710–22.
Westrop GD, et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol. 1989;63(3):1338–44.
Kawamura N, et al. Determinants in the 5’ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol. 1989;63(3):1302–9.
Moss EG, O’Neill RE, Racaniello VR. Mapping of attenuating sequences of an avirulent poliovirus type 2 strain. J Virol. 1989;63(5):1884–90.
Guest S, et al. Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3. J Virol. 2004;78(20):11097–107.
Kauder SE, Racaniello VR. Poliovirus tropism and attenuation are determined after internal ribosome entry. J Clin Invest. 2004;113(12):1743–53.
He Y, et al. Complexes of poliovirus serotypes with their common cellular receptor, CD155. J Virol. 2003;77(8):4827–35.
Iwasaki A, et al. Immunofluorescence analysis of poliovirus receptor expression in Peyer’s patches of humans, primates, and CD155 transgenic mice: implications for poliovirus infection. J Infect Dis. 2002;186(5):585–92.
Gonzalez H, et al. Intravenous immunoglobulin treatment of the post-polio syndrome: sustained effects on quality of life variables and cytokine expression after one year follow up. J Neuroinflammation. 2012;9:167.
Girard S, et al. Restriction of poliovirus RNA replication in persistently infected nerve cells. J Gen Virol. 2002;83(Pt 5):1087–93.
Baj A, et al. Post-poliomyelitis syndrome as a possible viral disease. Int J Infect Dis. 2015;35:107–16.
Minor PD. The polio-eradication programme and issues of the end game. J Gen Virol. 2012;93(Pt 3):457–74.
Connor RI, et al. Mucosal immunity to poliovirus. Mucosal Immunol. 2022;15(1):1–9.
Wright PF, et al. Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. J Infect Dis. 2014;209(10):1628–34.
Lockhart A, Mucida D, Parsa R. Immunity to enteric viruses. Immunity. 2022;55(5):800–18.
Herremans TM, et al. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol. 1999;162(8):5011–8.
Resik S, et al. Does simultaneous administration of bivalent (types 1 and 3) oral poliovirus vaccine and inactivated poliovirus vaccine induce mucosal cross-immunity to poliovirus type 2? Clin Infect Dis. 2018;67(suppl_1):S51–6.
Brickley EB, et al. Intestinal immune responses to type 2 oral polio vaccine (OPV) challenge in infants previously immunized with bivalent OPV and either high-dose or standard inactivated polio vaccine. J Infect Dis. 2018;217(3):371–80.
Valtanen S, et al. Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion. J Infect Dis. 2000;182(1):1–5.
Wright PF, et al. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants. Lancet Infect Dis. 2016;16(12):1377–84.
Macklin GR, et al. Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis. Lancet Infect Dis. 2019;19(10):1121–8.
Grassly NC, et al. Waning intestinal immunity after vaccination with oral poliovirus vaccines in India. J Infect Dis. 2012;205(10):1554–61.
Brickley EB, et al. Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden. BMJ Glob Health. 2019;4(4):e001613.
Abbink F, et al. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis. 2005;191(6):990–9.
Sato S, Kiyono H, Fujihashi K. Mucosal immunosenescence in the gastrointestinal tract: a mini-review. Gerontology. 2015;61(4):336–42.
Larocca AMV, Bianchi FP, Bozzi A, Tafuri S, Stefanizzi P, Germinario CA. Long-term immunogenicity of inactivated and oral polio vaccines: An Italian retrospective cohort study. Vaccines (Basel). 2022;10(8):1329. https://doi.org/10.3390/vaccines10081329.
Bosch X. Post-polio syndrome recognised by European parliament. Lancet Neurol. 2004;3(1):4.
Ragonese P, et al. Prevalence and risk factors of post-polio syndrome in a cohort of polio survivors. J Neurol Sci. 2005;236(1–2):31–5.
Meiner Z, et al. Risk factors for functional deterioration in a cohort with late effects of poliomyelitis: a ten-year follow-up study. NeuroRehabilitation. 2021;49(3):491–9.
Kay L, et al. Neurological symptoms in danes with a history of poliomyelitis: lifelong follow-up of late symptoms, their association with initial symptoms of polio, and presence of postpolio syndrome. Eur Neurol. 2018;80(5–6):295–303.
Lo JK, Robinson LR. Postpolio syndrome and the late effects of poliomyelitis. Part 1. pathogenesis, biomechanical considerations, diagnosis, and investigations. Muscle Nerve. 2018;58(6):751–9.
Kang JH, Lin HC. Comorbidity profile of poliomyelitis survivors in a Chinese population: a population-based study. J Neurol. 2011;258(6):1026–33.
Nielsen NM, et al. Long-term mortality after poliomyelitis. Epidemiology. 2003;14(3):355–60.
Nielsen NM, et al. Cancer risk in a cohort of polio patients. Int J Cancer. 2001;92(4):605–8.
Lin MC, et al. Pulmonary function and spinal characteristics: their relationships in persons with idiopathic and postpoliomyelitic scoliosis. Arch Phys Med Rehabil. 2001;82(3):335–41.
Schwartz I, et al. The association between post-polio symptoms as measured by the index of post-polio sequelae and self-reported functional status. J Neurol Sci. 2014;345(1–2):87–91.
Amtmann D, et al. Symptom profiles in individuals aging with post-polio syndrome. J Am Geriatr Soc. 2013;61(10):1813–5.
Oluwasanmi OJ, et al. Postpolio syndrome: a review of lived experiences of patients. Int J Appl Basic Med Res. 2019;9(3):129–34.
Wendebourg MJ, et al. Spinal cord gray matter atrophy is associated with functional decline in post-polio syndrome. Eur J Neurol. 2022;29(5):1435–45.
Brogardh C, Lexell J and Hammarlund CS. The influence of walking limitations on daily life: a mixed-methods study of 14 persons with late effects of polio. Int J Environ Res Public Health, 2022;19(13).
Brogardh C, Lexell J, and Hammarlund CS. Fall-related activity avoidance among persons with late effects of polio and its influence on daily life: a mixed-methods study. Int J Environ Res Public Health, 2021;18(13).
Nkowane BM, et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA. 1987;257(10):1335–40.
Kew OM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587–635.
Cann AJ, et al. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res. 1984;12(20):7787–92.
Evans DM, et al. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature. 1985;314(6011):548–50.
Kew OM, et al. Multiple genetic changes can occur in the oral poliovaccines upon replication in humans. J Gen Virol. 1981;56(Pt 2):337–47.
Foiadelli T, et al. Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis. BMC Infect Dis. 2016;16:277.
Kapusinszky B, et al. Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunol Med Microbiol. 2010;58(2):211–7.
Martinez CV, et al. Shedding of sabin poliovirus type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine. J Infect Dis. 2004;190(2):409–16.
Guo J, et al. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine. 2015;33(10):1235–42.
Alleman MM, et al. Update on vaccine-derived poliovirus outbreaks - worldwide, January 2020-June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(49):1691–9.
Alleman MM, et al. Update on vaccine-derived poliovirus outbreaks - worldwide, July 2019-February 2020. MMWR Morb Mortal Wkly Rep. 2020;69(16):489–95.
Jorba J, et al. Update on vaccine-derived poliovirus outbreaks - worldwide, January 2018-June 2019. MMWR Morb Mortal Wkly Rep. 2019;68(45):1024–8.
Garon J, et al. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines. 2016;15(6):693–708.
Voorman A, Lyons H, Bennette C, Kovacs S, Makam JK, F Vertefeuille J, Tallis G. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine. Vaccine. 2022:S0264-410X(22)00277-8. https://doi.org/10.1016/j.vaccine.2022.03.013.
Blake IM, et al. Type 2 poliovirus detection after global withdrawal of trivalent oral vaccine. N Engl J Med. 2018;379(9):834–45.
Patel M, et al. Polio endgame: the global introduction of inactivated polio vaccine. Expert Rev Vaccines. 2015;14(5):749–62.
Khetsuriani N, et al. Responding to a cVDPV1 outbreak in Ukraine: implications, challenges and opportunities. Vaccine. 2017;35(36):4769–76.
Al-Qassimi MA, et al. Circulating vaccine derived polio virus type 1 outbreak, Saadah governorate, Yemen, 2020. BMC Infect Dis. 2022;22(1):414.
Link-Gelles R, et al. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater - New York, June-August 2022. MMWR Morb Mortal Wkly Rep. 2022;71(33):1065–8.
Wise J. Poliovirus is detected in sewage from north and east London. BMJ. 2022;377: o1546.
Hill M, Bandyopadhyay AS, Pollard AJ. Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use. Lancet. 2022;400(10354):713–5.
Macadam AJ, et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J Virol. 2006;80(17):8653–63.
Yeh MT, et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe. 2020;27(5):736-751.e8.
Konopka-Anstadt JL, et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines. 2020;5(1):26.
Wahid R, et al. Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses. NPJ Vaccines. 2021;6(1):94.
De Coster I, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2021;397(10268):39–50.
Saez-Llorens X, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet. 2021;397(10268):27–38.
Wahid R, et al. Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children. NPJ Vaccines. 2022;7(1):19.
Funding
This research was partially funded by the Universidad of Buenos Aires (UBACYT N°20020190100119BA to JQ).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Quarleri, J. Poliomyelitis is a current challenge: long-term sequelae and circulating vaccine-derived poliovirus. GeroScience 45, 707–717 (2023). https://doi.org/10.1007/s11357-022-00672-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11357-022-00672-7